Bayer Pulls Trasylol at FDAs Request

Defective Drugs

A month and a half after a Food and Drug Administration (FDA) panel voted to keep Bayer’s Trasylol on the market, Bayer voluntarily pulled it. The drug, an anti-bleeding agent, had been found, in two studies published in 2006, to double the risk of kidney failure after being used in patients undergoing heart-bypass surgery. The panel recommended that additional studies should be conducted to prove whether the drug was really dangerous. Apparently, Bayer already knew the answer to that question.

After consulting with the FDA and its equivalent bodies in Germany and Canada, and facing declining profits from the drug as patients voluntarily refused it in the wake of the published studies, Bayer AG decided the withdrawal was the best course of action.

Although the drug is not being taken off the market, it is already too late for some people, as nearly five million people have been given the drug over the past 14 years. If you or someone you love has suffered kidney failure, or if you’ve lost a loved one due to the defective prescription drug Trasylol, contact today to get in touch with a defective drug lawyer in your area.